生物制药公司Mirum Pharmaceuticals, Inc.（股票代码：MIRM）今日盘前大涨7.70%，主要受益于公司发布的强劲第二季度财报以及上调的全年业绩指引。
根据公司公告，Mirum第二季度总营收达到1.28亿美元，表现优异。其中，公司的主打产品LIVMARLI销售额为8820万美元，同比增长87%，展现出强劲的市场需求。另一款胆汁酸药物的销售额为3960万美元，同比增长30%。鉴于良好的商业表现，Mirum将2025年全年营收指引上调至4.9亿至5.1亿美元，进一步提振了投资者信心。
除了财务业绩亮眼外，Mirum的药物研发管线也取得重要进展。公司预计在本季度完成volixibat用于治疗原发性硬化性胆管炎的VISTAS研究患者入组，顶线数据有望在2026年第二季度公布。此外，公司的现金状况良好，截至2025年6月30日，Mirum的无限制现金、现金等价物和投资总额达3.217亿美元，较2024年底有所增加，为公司未来发展提供了充足的资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.